Long-Acting Beta-Agonists in Adult Asthma: Evidence that these Drugs are Safe

Nelson, Harold S.

doi:10.1016/j.pcrj.2006.08.006

Cited by 23 publications

(19 citation statements)

References 30 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,36 However, there is no evidence of any increased risk when a LABA is used in conjunction with ICS for asthma. 37 The level at which add-on therapy should begin cannot be defined completely, but all adults given a LABA should be on at least 200mcg of BDP-equivalent ICS a day, and no patient should be on >800mcg ICS without a prior trial of a LABA. Although the …”

Section: Regular Preventer Therapy: Stepmentioning

confidence: 99%

Summary of the 2008 BTS/SIGN British Guideline on the Management of Asthma

Levy

Thomas

Small

et al. 2009

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryThe 2008 BTS/SIGN British Guideline on the management of asthma provides comprehensive updated evidence-based guidance on asthma management for healthcare professionals. This primary care-focussed summary has been produced to aid dissemination and implementation of the key guideline messages into primary care. The section on diagnosis emphasises the new integrated symptombased approach with clinicians using their deductive skills to determine the probability that the patient has asthma. The various tools used for monitoring asthma are discussed. There are sections on both non-pharmacological and pharmacological management of chronic asthma in adults and children. Treatment options for children are subdivided into the under-5s and children aged 5-12 years. Poor asthma control is manifested by exacerbations and acute asthma. Personalised asthma action plans for guided self management should be provided and used when levels of asthma control change. There are sections on difficult asthma and the treatment of exacerbations and acute severe asthma. Various outcome measures for auditing the quality of asthma care are discussed.

show abstract

Section: Regular Preventer Therapy: Stepmentioning

confidence: 99%

Summary of the 2008 BTS/SIGN British Guideline on the Management of Asthma

Levy

Thomas

Small

et al. 2009

Primary Care Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…When used in conjunction with ICS, LABAs are safe. 10,11 Thus, he summarises that excellent control at lower doses of ICS could be attained with once-daily combination therapy, even though there is no world guideline yet recommending this treatment option for mild asthma.…”

Section: R E P R O D U C T I O N P R O H I B I T E Dmentioning

confidence: 99%

Treatment of mild persistent asthma

Kaplan

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

SummaryThere are several treatment options available for patients who have mild persistent asthma. After being shown a typical case study and three possible treatment options, three respiratory specialists each selected a different option. The options were: using a combination beclometasone/albuterol inhaler on an as-needed basis; daily treatment with an oral leukotriene receptor antagonist together with asneeded use of a short-acting beta2-agonist (SABA) inhaler; and using a combination inhaled corticosteroid/long-acting beta2-agonist inhaler once-daily together with as-needed SABA. The evidence for each option is reviewed in the light of recent research.

show abstract

“…This critical review presents a pharmacist's perspective of the cardiovascular adverse effects (AE) of respiratory Beta-2 agonists are bronchodilators that are commonly used for asthma and COPD, which selectively bind to beta-2 receptors primarily found at the airways. [3][4][5][6] Nonselective beta-agonists (e.g. isoprenaline) will activate beta-1 receptors at the cardiovascular system, contributing to higher mortality.…”

Section: Introductionmentioning

confidence: 99%

“…isoprenaline) will activate beta-1 receptors at the cardiovascular system, contributing to higher mortality. 3,4 However, studies found that even highly selective beta-2 agonists can affect the heart. 7 Inhaled beta-2 agonists are generally categorised into short-acting (SABA) and long-acting (LABA).…”

Section: Introductionmentioning

confidence: 99%

“…7 Inhaled beta-2 agonists are generally categorised into short-acting (SABA) and long-acting (LABA). [3][4][5] Although highly selective, they are known to be associated with extra-pulmonary effects such as tremor, palpitations, headache, hyperglycaemia, and decreased serum potassium levels, as well as potentially contributing to ischemia and heart failure (HF). 6,[8][9][10][11][12][13][14] It is believed that these effects are related to systemic absorption of the drug.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation